Article Details

Sun Pharma's Leqselvi has potential for rapid uptake in US alopecia areata market, says GlobalData

Retrieved on: 2025-04-11 10:35:43

Tags for this article:

Click the tags to see associated articles and topics

Sun Pharma's Leqselvi has potential for rapid uptake in US alopecia areata market, says GlobalData. View article details on hiswai:

Excerpt

The JAK 1/2 inhibitor was approved by the FDA in July 2024 for treatment of adults with severe alopecia areata (AA); however, a patent ruling in ...

Article found on: www.globaldata.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up